(UroToday.com) For patients with muscle-invasive, localized bladder cancer, neoadjuvant chemotherapy followed by radical cystectomy or trimodal therapy are accepted treatment options. Those who are cisplatin-ineligible/unfit for surgery, or have locally advanced and unresectable disease, have limited treatment options. In a plenary abstract presentation in the Rapid Abstract Session: Urothelial Carcinoma and Rare Tumors session at the 2021 ASCO GU Cancers Symposium, Dr. Monika Joshi presented results of the DUART trial investigating the combination of radiation therapy (RT) and checkpoint inhibitor, durvalumab.